{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:59:50Z","timestamp":1790744390667,"version":"4.1.0"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"26","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,27]]},"abstract":"<jats:p>\n                    Ventilator-associated pneumonia (VAP) is one of the most common and serious infections in hospitalized patients. VAP is associated with worse outcomes and significant morbidity and mortality worldwide. Our primary goal in this study was to identify the VAP pathogen with its distribution characteristics, clarify risk factors, prognosis, and outcomes, and help reduce associated morbidity and mortality. This retrospective observational study was conducted between June 2019 and June 2022 in 3 general intensive care units of a training and research hospital. Data on demographic, clinical and laboratory parameters were collected retrospectively from medical cards and electronic records. A total of 204 patients were diagnosed with VAP caused by Gram-negative microorganisms. Chronic renal failure (RF) and neurological diseases were significantly associated with mortality (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.01,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.023). The duration of mechanical ventilation before VAP and the duration of mechanical ventilation were significantly longer in survivors compared to non-survivors. The number of patients with early VAP was significantly higher, and the days of VAP were shorter in the non-survivors compared to the survivors (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.006,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.016). The number of VAP episodes (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.0001), the presence of RF, acute respiratory distress syndrome, bacteremia, and sepsis before VAP (&lt;48 hours) were associated with mortality. Intensive care unit and the length of hospital stay were significantly shorter in non-survivors than in survivors (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.0003,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.0001). Administration of monotherapy, inadequate empirical antibiotic therapy, inadequate antibiotic therapy (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.004,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.002, and\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.0006), persistence of the pathogen (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.0001), C-reactive protein and procalcitonin levels (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.002,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.041) were associated with mortality. The presence of neurological diseases and RF was associated with a greater likelihood of mortality in patients with VAP. As risk factors, early-onset VAP, presence of RF\u2013acute respiratory distress syndrome\u2013bacteremia\u2013sepsis 48 hours before VAP, organ failure, need for hemodialysis, shock and the persistence of the pathogen increased the risk of mortality.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000042946","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T15:00:40Z","timestamp":1751295640000},"page":"e42946","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Characteristics of ventilator-associated pneumonia due to Gram-negative bacteria in the intensive care unit: A single-center experience"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7462-3134","authenticated-orcid":false,"given":"Sinem","family":"Bayrak\u00e7i","sequence":"first","affiliation":[{"name":"Department of Intensive Care Unit, Gaziantep City Hospital, Gaziantep, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-8293","authenticated-orcid":false,"given":"Ahmet","family":"\u015eahin","sequence":"additional","affiliation":[{"name":"Dr. Ersin Arslan Training and Research Hospital Infectious Diseases and Clinical Microbiology Department, Gaziantep, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8681-3931","authenticated-orcid":false,"given":"Onur","family":"Bayrak\u00e7i","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Gaziantep City Hospital, Gaziantep, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8695-7118","authenticated-orcid":false,"given":"Selda","family":"Aslan","sequence":"additional","affiliation":[{"name":"Gaziantep City Hospital Hospital Infectious Diseases and Clinical Microbiology Department, Gaziantep, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260813","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cnc.2016.09.012","article-title":"Hospital-acquired infections: current trends and prevention.","volume":"29","author":"Boev","year":"2017","journal-title":"Crit Care Nurs Clin North Am"},{"key":"R2-20260813","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1128\/CMR.00027-10","article-title":"Hospital epidemiology and infection control in acute-care settings.","volume":"24","author":"Sydnor","year":"2011","journal-title":"Clin Microbiol Rev"},{"key":"R3-20260813","doi-asserted-by":"crossref","first-page":"1700582","DOI":"10.1183\/13993003.00582-2017","article-title":"International ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: guidelines for the management of hospital-acquired pneumonia (HAP)\/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociaci\u00f3n Latinoamericana del T\u00f3rax (ALAT).","volume":"50","author":"Torres","year":"2017","journal-title":"Eur Respir J"},{"key":"R4-20260813","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","article-title":"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.","volume":"171","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"R5-20260813","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American Thoracic Society.","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R6-20260813","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/QCO.0000000000000596","article-title":"An overview of guidelines for the management of hospital-acquired and ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria.","volume":"32","author":"Cill\u00f3niz","year":"2019","journal-title":"Curr Opin Infect Dis"},{"key":"R7-20260813","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1164\/ajrccm.165.7.2105078","article-title":"Ventilator-associated pneumonia.","volume":"165","author":"Chastre","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"R8-20260813","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/MCP.0b013e32835f27be","article-title":"Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management.","volume":"19","author":"Barbier","year":"2013","journal-title":"Curr Opin Pulm Med"},{"key":"R9-20260813","doi-asserted-by":"crossref","first-page":"e0227139","DOI":"10.1371\/journal.pone.0227139","article-title":"Impact of multi-drug resistant bacteria on economic and clinical outcomes of healthcare-associated infections in adults: systematic review and meta-analysis.","volume":"15","author":"Serra-Burriel","year":"2020","journal-title":"PLoS One"},{"key":"R10-20260813","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"R11-20260813","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/cc5974","article-title":"Staffing level: a determinant of late-onset ventilator-associated pneumonia.","volume":"11","author":"Hugonnet","year":"2007","journal-title":"Crit Care"},{"key":"R12-20260813","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jgar.2016.12.016","article-title":"Epidemiology of multidrug-resistant Gram-negative pathogens isolated from ventilator-associated pneumonia in ICU patients.","volume":"9","author":"Gupta","year":"2017","journal-title":"J Glob Antimicrob Resist"},{"key":"R13-20260813","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1086\/653059","article-title":"End points in hospital-acquired pneumonia and\/or ventilator associated pneumonia clinical trials: food and drug administration perspective.","volume":"51","author":"Laessig","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"R14-20260813","first-page":"S93","article-title":"Organisms associated with ventilator associated pneumonia in intensive care unit.","volume":"18","author":"Talha","year":"2009","journal-title":"Mymensingh Med J"},{"key":"R15-20260813","article-title":"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired and ventilator associated pneumonia in adults","author":"Klompas","year":"2022"},{"key":"R16-20260813","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1128\/AAC.02109-13","article-title":"Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia.","volume":"58","author":"Luyt","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R17-20260813","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccm.2016.07.008","article-title":"Preventing ventilator-associated infections.","volume":"37","author":"Mehta","year":"2016","journal-title":"Clin Chest Med"},{"key":"R18-20260813","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jiph.2014.07.005","article-title":"Incidence and attributable costs of ventilator-associated pneumonia (VAP) in a tertiary-level intensive care unit (ICU) in northern India.","volume":"8","author":"Mathai","year":"2015","journal-title":"J Infect Public Health"},{"key":"R19-20260813","first-page":"165","article-title":"Ventilator-associated pneumonia in the ICU: microbiological Profile.","volume":"4","author":"Rana","year":"2017","journal-title":"J Bacteriol Mycol"},{"key":"R20-20260813","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.mpaic.2012.02.009","article-title":"Nosocomial infections in the intensive care unit.","volume":"13","author":"Majumdar","year":"2012","journal-title":"Anaesth Intensive Care Med"},{"key":"R21-20260813","first-page":"e23634","article-title":"Trends and factors associated with ventilator-associated pneumonia: a national perspective.","volume":"14","author":"Shah","year":"2022","journal-title":"Cureus"},{"key":"R22-20260813","first-page":"1083","article-title":"Ventilator-associated pneumonia is more common and of less consequence in trauma patients compared with other critically ill patients.","volume":"69","author":"Cook","year":"2010","journal-title":"J Trauma"},{"key":"R23-20260813","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3855\/jidc.12012","article-title":"Microbiological profile of ventilator-associated pneumonia among intensive care unit patients in tertiary Egyptian hospitals.","volume":"14","author":"Farag","year":"2020","journal-title":"J Infect Dev Ctries"},{"key":"R24-20260813","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40560-015-0077-4","article-title":"Prognostic factors associated with mortality of drug-resistant Acinetobacter baumannii ventilator-associated pneumonia.","volume":"3","author":"Inchai","year":"2015","journal-title":"J Intensive Care"},{"key":"R25-20260813","first-page":"410","article-title":"A nationwide retrospective analysis of ventilator-associated pneumonia in the US.","volume":"35","author":"Shaka","year":"2022","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"R26-20260813","doi-asserted-by":"crossref","first-page":"440","DOI":"10.4103\/0971-5916.198679","article-title":"Antibiotic resistance andpathogen profile in ventilator-associated pneumonia in a tertiary care hospital in India.","volume":"144","author":"Chaudhury","year":"2016","journal-title":"Indian J Med Res"},{"key":"R27-20260813","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.3346\/jkms.2021.36.e251","article-title":"The distribution of multidrug-resistant microorganisms and treatment status of hospital-acquired pneumonia\/ventilator-associated pneumonia in adult intensive care units: a prospective cohort observational study.","volume":"36","author":"Chang","year":"2021","journal-title":"J Korean Med Sci"},{"key":"R28-20260813","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.3390\/healthcare10091765","article-title":"Ventilator-associated pneumonia caused by multidrug-resistant gram-negative bacteria in vietnam: antibiotic resistance, treatment outcomes, and colistin-associated adverse effects.","volume":"10","author":"Vo","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"R29-20260813","first-page":"490","article-title":"Causative agents and resistance among hospital-acquired and ventilator-associated pneumonia patients at Srinagarind Hospital, Northeastern Thailand.","volume":"44","author":"Reechaipichitkul","year":"2013","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"R30-20260813","article-title":"HoChiMinh city respiratory society carbapenem resistance of Pseudomonas aeruginosa and Acinetobacter baumannii causing nosocomial pneumonia and VAP at the intensive care unit in Nguyen Tri Phuong Hospital.","year":"2016"},{"key":"R31-20260813","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/IDR.S67267","article-title":"Microbiology, resistance patterns, and risk factors of mortality in ventilator-associated bacterial pneumonia in a Northern Thai tertiary-care university based general surgical intensive care unit.","volume":"7","author":"Chittawatanarat","year":"2014","journal-title":"Infect Drug Resist"},{"key":"R32-20260813","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1007\/s00134-006-0355-7","article-title":"Impact of piperacillin resistance on the outcome of Pseudomonas ventilator-associated pneumonia.","volume":"32","author":"Combes","year":"2006","journal-title":"Intensive Care Med"},{"key":"R33-20260813","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1086\/500318","article-title":"Excess risk of death from intensive care unit-acquired nosocomial bloodstream infections: a reappraisal.","volume":"42","author":"Garrouste-Org\u00e9as","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R34-20260813","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12890-021-01415-8","article-title":"Microorganisms and clinical outcomes of early- and late-onset ventilator-associated pneumonia at Srinagarind Hospital, a tertiary center in Northeastern Thailand.","volume":"21","author":"Arayasukawat","year":"2021","journal-title":"BMC Pulm Med"},{"key":"R35-20260813","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3390\/idr13020038","article-title":"Antimicrobial susceptibility among pathogens isolated in early- versus late-onset ventilator-associated pneumonia.","volume":"13","author":"Ben Lakhal","year":"2021","journal-title":"Infect Dis Rep"},{"key":"R36-20260813","doi-asserted-by":"crossref","first-page":"897.e13","DOI":"10.1016\/j.amjmed.2005.12.034","article-title":"Predictors of long-term mortality in patients with ventilator-associated pneumonia.","volume":"119","author":"Ranes","year":"2006","journal-title":"Am J Med"},{"key":"R37-20260813","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1440-1797.2006.00567.x","article-title":"Incidence and risk factors for the development of acute renal failure in patients with ventilator-associated pneumonia.","volume":"11","author":"Gursel","year":"2006","journal-title":"Nephrology (Carlton)"},{"key":"R38-20260813","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1186\/cc11312","article-title":"Ventilator-associated pneumonia and ICU mortality in severe ARDS patients ventilated according to a lung-protective strategy.","volume":"16","author":"Forel","year":"2012","journal-title":"Crit Care"},{"key":"R39-20260813","doi-asserted-by":"crossref","first-page":"e20200569","DOI":"10.36416\/1806-3756\/e20200569","article-title":"Ventilator-associated pneumonia in patients on prolonged mechanical ventilation: description, risk factors for mortality, and performance of the SOFA score.","volume":"47","author":"N\u00fa\u00f1ez","year":"2021","journal-title":"J Bras Pneumol"},{"key":"R40-20260813","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1007\/s00134-020-05980-0","article-title":"Ventilator-associated pneumonia in adults: a narrative review.","volume":"46","author":"Papazian","year":"2020","journal-title":"Intensive Care Med"},{"key":"R41-20260813","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1183\/09031936.00086707","article-title":"Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia.","volume":"31","author":"Ramirez","year":"2008","journal-title":"Eur Respir J"},{"key":"R42-20260813","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1469-0691.2004.01044.x","article-title":"C-reactive protein as a marker of infection in critically ill patients.","volume":"11","author":"Povoa","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"R43-20260813","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jhin.2006.12.019","article-title":"Inadequate treatment of ventilator-associated pneumonia: risk factors and impact on outcomes.","volume":"65","author":"Teixeira","year":"2007","journal-title":"J Hosp Infect"},{"key":"R44-20260813","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.medcli.2011.06.024","article-title":"Multidrug and carbapenem-resistant Acinetobacter baumannii infections: factors associated with mortality.","volume":"138","author":"Hern\u00e1ndez-Torres","year":"2012","journal-title":"Med Clin (Barc)"},{"key":"R45-20260813","doi-asserted-by":"crossref","first-page":"e52349","DOI":"10.1371\/journal.pone.0052349","article-title":"Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients.","volume":"7","author":"Shields","year":"2012","journal-title":"PLoS One"},{"key":"R46-20260813","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1469-0691.2006.01601.x","article-title":"Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome.","volume":"13","author":"Kuo","year":"2007","journal-title":"Clin Microbiol Infect"},{"key":"R47-20260813","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.12659\/MSM.905919","article-title":"Prognostic risk factors in ventilator-associated pneumonia.","volume":"24","author":"Karakuzu","year":"2018","journal-title":"Med Sci Monit"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000042946","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:00:23Z","timestamp":1786633223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000042946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":47,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042946","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]}}}